Clinical trial · Observational
Recommendations for the Treatment of Children With Burkitt's Lymphoma
NCT04425421CI-TRIAL-00104314GFALMB2019recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Burkitt Lymphoma | Burkitt Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OBSERVATIONAL | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All children with Burkitt lymphoma and in 2 units the addition of Rituximab
- description
- An amendment has been added to give 4 injections during induction treatments as in the study in adults, that is to say 1 injection on D1 and D6 of each induction treatment, COPM or COPADM depending on the risk group in two centers. It is an amendment of the therapeutic recommendations "GFA LMB2019" which are the basis, the other centers will continue with this GFALMB2019 protocol as is
- interventionNames
- Other: OBSERVATIONAL
Primary outcomes (5)
- measure
- Evaluation of the number of cases with local disease.
- timeFrame
- 5 years
- description
- evaluating the initial clinical reports and later histological reports to confirm the diagnosis and the stage.
- measure
- Evaluation of the number of cases by stage at the time of diagnosis.
- timeFrame
- 5 Years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment. \- Exclusion Criteria: Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.
References
Publications (0)
Data not yet available
No reference posted for this study.